Center Laboratories (4123) reported revenue of NT$142.9 million for Oct 2026, +6.1% year on year and -17.7% from the previous month. Revenue for Jan–Oct 2026 was NT$1.52 billion (+21.6% year on year).
Year-on-year revenue growth: 8 months in a row. →
In Oct 2026, it ranked No. 58 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$142.9 million | +6.1% | -17.7% |
| Sep 2026 | NT$173.5 million | +33.3% | +15.0% |
| Aug 2026 | NT$151 million | +61.5% | -3.6% |
| Jul 2026 | NT$156.5 million | +15.3% | +34.6% |
| Jun 2026 | NT$116.3 million | +2.9% | -16.0% |
| May 2026 | NT$138.5 million | +8.1% | -21.9% |
| Apr 2026 | NT$177.3 million | +28.3% | +19.9% |
| Mar 2026 | NT$147.9 million | +55.6% | +16.6% |
| Feb 2026 | NT$126.8 million | -21.1% | -33.7% |
| Jan 2026 | NT$191.3 million | +56.4% | +27.6% |
| Dec 2025 | NT$149.9 million | +24.4% | +30.5% |
| Nov 2025 | NT$114.9 million | -13.4% | -14.7% |
| Oct 2025 | NT$134.7 million | -31.5% | +3.5% |
| Sep 2025 | NT$130.2 million | +23.5% | +39.3% |
| Aug 2025 | NT$93.5 million | -36.7% | -31.2% |
| Jul 2025 | NT$135.8 million | -3.3% | +20.2% |
| Jun 2025 | NT$113 million | -6.2% | -11.8% |
| May 2025 | NT$128.1 million | -15.1% | -7.3% |
| Apr 2025 | NT$138.2 million | -2.1% | +45.3% |
| Mar 2025 | NT$95.1 million | -18.6% | -40.8% |
| Feb 2025 | NT$160.7 million | +70.9% | +31.4% |
| Jan 2025 | NT$122.3 million | -19.8% | +1.4% |
| Dec 2024 | NT$120.6 million | -16.9% | -9.1% |
| Nov 2024 | NT$132.7 million | +4.7% | -32.5% |
| Oct 2024 | NT$196.7 million | +47.2% | +86.6% |
Jan–Oct 2026 cumulative: NT$1.52 billion (+21.6% YoY)
Other Biotech & Medical companies
Compare with peers: Center Laboratories vs PEC / Center Laboratories vs Lotus Pharm / Center Laboratories vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16